INFLAMMATION & ITS SEQUELAE IN IBD FOLLOWING INFLIXIMAB

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 克罗恩病和溃疡性结肠炎是与全身炎症相关的炎性肠病（IBD）。 这种炎症反过来又与食欲不振，生长障碍和青春期延迟有关。 英夫利西单抗是一种TNF-α的单克隆抗体，最近已被批准用于儿科。 虽然已知长期使用英夫利西单抗可改善患者的生活质量（QOL），但尚未研究其短期变化。 此外，尚不清楚英夫利西单抗是否能改善与生长和青春期相关的激素水平。 我们建议在英夫利西单抗输注前、输注后2天和输注后2周检测炎症体征-血清CRP和粪便乳铁蛋白。 我们还将检测与生长和青春期相关的激素水平，包括IGF-1、促黄体生成素、雌二醇和睾酮，并确定食欲和生活质量指标的变化。 这些知识将有助于确定对治疗的正常反应，并使医生能够滴定英夫利西单抗的剂量，并就治疗的预期向患者提供咨询。 了解与生长和青春期相关的激素反应将更好地表征炎症对这些过程的影响，并有助于表明英夫利昔单抗是否可能改善IBD儿童的生长。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBD) that are associated with systemic inflammation. This inflammation is in turn linked to poor appetite, growth failure and delayed puberty. Infliximab is a monoclonal antibody to TNF-alpha that has recently been approved for use in pediatrics. Though it is known that long-term use of infliximab improves patients' quality of life (QOL), the short-term changes have not been studied. Additionally, it is not known whether infliximab improves levels of hormones related to growth and puberty. We propose to test for signs of inflammation-serum CRP and fecal lactoferrin-prior to, 2 days after and 2 weeks after an infusion of infliximab. We will also test for levels of hormones related to growth and puberty-including IGF-1, leutinizing hormone, estradiol and testosterone-and determine changes in measures of appetite and QOL. Such knowledge would be useful in defining normal response to therapy and in equipping physicians to titrate doses of infliximab and counsel patients regarding what to expect from treatment. Knowing the response of hormones related to growth and puberty will better characterize the effects of inflammation on these processes and help indicate whether infliximab might improve growth in children with IBD.